Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seven and a half cents doesn't mean a hell of a lot, Seven and a half cents doesn't mean a thing.
The market closes at 4PM today not 2PM. Stay around to FFTC which may be very interesting.
As I recall, the market used to close early on the Friday after Thanksgiving as most traders were not around and the market usually had its lowest volume on that day.
Respectfully there is a big difference between the last "run" which was based upon the Anti drug abuse technology of the Sequestox formulation and today's corporation which has actual sales and R&D for new high revenue ANDAs. Apparently NH has decided that if you can't beat them, join them; hence the decision to now try to manufacture opioid generics and specifically Oxycontin.
Ironically, if Purdue loses its case against Elite and Elite gets FDA approval for OXY, a bidding war to purchase Elite is likely to occur.
Many here have missed the anniversary and/or got bagged when they didn't take money off the table before SequestOx failed. So congratulations.
She was just 17, you know what I mean.
Cause I owe my soul.
Saint Peter don't call me., I will not come.
t
You load 16 tons and what do you get?
Wake up little Suzie . Wake up.
By now you should have figured out that the daily short sale volume as reported by Finra is not a very good indicator of present or future stock action. A better investment criteria is looking at actual results and future possibilities based on R&D.
There is only one bet to make on this stock: Does Multikine help people with head and neck cancer survive or live longer than those who do not take this treatment. If the results are positive, this company and its shareholders will be a successful.
As for shorting of stocks, with a price this low few investors, other than Market Makers, are participating. If you think about it, sometimes shorts are positive for investors, since, except for bankruptcy, they eventually have to cover and buy to close the position. Ever hear of a short squeeze.
He who sells what isnt' hisn, mst buy it back or go to end prisn- Daniel Drew.
As the late great Tug McGraw used to say: You gotta believe! Lets go Elite!
Pyros launched its Vigpoder Vigabatrin generic in April; therefore the manufacturing revenue Elite receives will not be revealed until the current quarter's statement due in August. Hopefully NH will mention it on the conference call next month so investors will get an idea as to how meaningful it is.
Slow and steady wins the race.
Market maker signal just posted. Expect a move today in either direction.
Check the date. But still nice to read. Stock was around .12 when originally published in October 8, 2023.
50 day simple moving average and exponentially weighted MA both sitting at .14. Bollinger bands are likewise very tight. Looking for a possible breakout to the upside in the near future. A qualified chartist opinion ( which is not my bailiwick) would be appreciated. When I saw her sanding there.
She was just 17, you know what I mean, but the way she walked was was way beyond compare.
More dilution with issuance of warrants at .35 exercise price. I hate warrants they often cause the holders to short the stock when it breached the exercise price to the upside. Hope they can avoid the dreaded reverse split which is often the end oaf the road.
Apparently the major brokerage houses such as Schwab do not show OTC BB news from services such as Accesswire. While I appreciate the work performed by Dianne, who performs other tasks beside IR, it would be nice to see a better effort to spread the word in the investment community. Perhaps NH should consider hiring an assistant to aid the PR efforts. I still do not see a SEC filing for this current event.
I remember having my Mom administer Tylenol with codeine. Unfortunately kids found ways to abuse its use. The upgraded dosage may be an indication that Elite is ready to launch in the near future.
It will be interesting to see the market size indications when the 8k is released on Monday. According to the shortage list, there are 8 other companies that serve the Methotrexate market. Hopefully Elite will launch during next quarter commencing on June 1 and Kirkov can continue his track record of upward trajectory of generic drug sales.
The stay was predicated on the pending similar claim brought by Purdue v. ACCORD. If that case is not decided by July 17, the stay will be extended.
Excellent due diligence guys. Thanks. Strong hands will help make this trade at fair value with a value appropriate pe ratio.
I think she already testified. Looks like a short squeeze.
After the final protocol is submitted to the FDA before June 21, enrollment of the 212 patients ( 106 for the control and 106 for the multikline users), will hopefully be concluded before the fall. Preliminary positive results should be confirmed within a few weeks thereafter according to the company.
Hopefully these events will be publicized. Stock is seriously undervalued and is deserving of a market cap that is tenfold of current prices. Long and strong here as a believer in the technology.
The kicker would be an approval of the MAA in the UK which will make this treatment the Standard of Care on the other side of the pond.
Perhaps the storm after the calm.
Feels like the calm before the storm.
Maxim Group was fined $800,000 on 9/29/23 for failing to monitor suspicious trading in otc securities. Welcome aboard.
MAXM added as a MM but my count is 12. The last time a new MM appeared the volume and price increased dramatically. Just sayin.
Mama don't take my kodachrome away!
A PE of around 30 for eltp would be a five bagger from current price or .65-.70 per share.
Current market cap is $134M. If the revenue stream rises to $20M per quarter, $80m per year, which is not unrealistic, a market cap of $675M seems just about right for a buyout of .65 per share. Just one guys opinion.
OMG. What will happen to the goats when the fuse is lit? Kaboom!!!
Do you think this event will have any effect on the pending standard of care application in the UK?
A clue to future price movement may be found in a review of the Historical Prices and Summary provided by IH. The average daily volume has decreased from 1.3 M to approximately .5 M over the last 6 months. Yesterdays volume of 1.3 million may be a harbinger of future volume increase bolstered by new interest in this company and stock. We shall see. GLTA.
Suppose you were recently hired by ELTP to work in the new warehouse that has recently been inspected by the FDA to assure it was kosher and halal. At lunch you discuss with fellow workers how busy the facility has been.
You tell your family that this is a growing public company that seems to be expanding and has added another shift.
You look up the stock price and see it is selling only for 14 cents and has a PE ratio around 6 and shows increasing quarterly revenues. Plus they have recently authorized shares to be issued to employees. Uncle Joe says this looks like a great company to invest in.
My point: Strong buy at these ridiculously low prices.
Would not be surprised to see a bit of news released regarding the R&D that is in the works. Highest volume today in weeks. Breaking above the 50 day Moving average of .1413.
Investor has to be crazy patient or a crazy patient. What a difference an A makes. Not sure which I am yet. but then again catch 22.
If quarterly revenues average $18-20M, a fiscal year projection of $76-80M before any approvals of the current pending ANDAs, it will be hard to maintain a price below .45-50 per share in my opinion. Many will be doing the shuuda, cudda , wuddas if that projection is correct. But then again, we may be up the creek without a Kayak to mix a metaphor.
What do you predict the stock price will be if the company does show $18-20M in revenue for the 4th quarter? Do you think it will stay in the .11-.13 range until the earnings are announced at the end of June some 7 weeks from now?
Hmm. I wonder if the stock will be .13 when the company announces a record quarter and record year in June. The people playing the long game should be happy to take advantage of the MMs who try to suppress the price.
Someone just beat me to the punch. Congrats. CDEL and ETRF unsuccessful since we know what we have. My guess is that the Emperor has some new clothes.